Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …

Background Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed
within 12 months of first-line therapy are at high risk for poor outcomes with current standard …

Background The prognosis of patients with early relapsed or refractory large B-cell
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of
care (SOC) as second-line therapy for primary refractory or early relapsed (≤ 12 months) …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …

Background Patients with relapsed or refractory large B-cell lymphoma after first-line
treatment who are not intended for haematopoietic stem-cell transplantation (HSCT) have …

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin
lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up …

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …